HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Clinical significance of the expression of endothelial-monocyte activating polypeptide II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).

AbstractBACKGROUND:
The application of human mutant recombinant TNF-alpha (TNF-SAM2) to glioblastoma has shown that there is marked variation in its sensitivity to TNF. To determine whether the production of endothelial-monocyte activating polypeptide II (EMAPII) by tumors confers TNF sensitivity and whether EMAPII expression in glioblastoma can predict the clinical response to TNF therapy, we evaluated EMAPII expression and the efficacy of TNF in patients with glioblastoma.
MATERIALS AND METHODS:
We analyzed EMAPII mRNA expression using reverse transcriptase-polymerase chain reaction (RT-PCR) of frozen tissue sections of glioblastoma and evaluated if there was any correlation between EMAPII expression and the response to TNF therapy in patients with glioblastoma.
RESULTS:
Amplified bands corresponding to EMAPII were obtained by RT-PCR in 8 out of 11 glioblastomas. There was a significant correlation between the time to tumor progression after TNF-SAM2 treatment and the expression of EMAPII (p < 0.05). Patients with positive expression of EMAPII in their tumor tissues tended to have longer progression-free survival.
CONCLUSION:
Variable responses to combined chemotherapy with mutant TNF-alpha (TNF-SAM2) might be explained by EMAPII expression in glioblastoma. EMAPII expression in glioblastoma might predict the clinical response to TNF therapy and potentially identify patients with cytokine-responsive tumors.
AuthorsM Yamamoto, T Fukushima, Y Ueno, S Hayashi, H Kimura, G Soma, M Tomonaga
JournalAnticancer research (Anticancer Res) 2000 Nov-Dec Vol. 20 Issue 6A Pg. 4081-6 ISSN: 0250-7005 [Print] Greece
PMID11131676 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cytokines
  • Neoplasm Proteins
  • RNA-Binding Proteins
  • Recombinant Proteins
  • TNF-SAM2
  • Tumor Necrosis Factor-alpha
  • small inducible cytokine subfamily E, member 1
Topics
  • Aged
  • Astrocytoma (drug therapy, metabolism, surgery)
  • Brain Neoplasms (drug therapy, metabolism, surgery)
  • Combined Modality Therapy
  • Cytokines
  • Female
  • Glioblastoma (drug therapy, metabolism, surgery)
  • Humans
  • Immunotherapy (methods)
  • Male
  • Middle Aged
  • Neoplasm Proteins (biosynthesis)
  • RNA-Binding Proteins (biosynthesis)
  • Recombinant Proteins (adverse effects, therapeutic use)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Necrosis Factor-alpha (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: